Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New candidate diabetes therapies developed in Japan

May 11, 2012

Research in Spain yields new candidate Gaucher's disease therapies

May 11, 2012

Cadila Healthcare discovers novel GPR119 receptor agonists

May 10, 2012

FDA advisory committee votes on new indication for Arcalyst

May 9, 2012

Apricus Biosciences to meet with Health Canada on Femprox

May 9, 2012

Isis begins phase II ISIS-APOCIIIRx study

May 7, 2012

Novel inhibitors of diacylglycerol O-acyltransferase 1 presented

May 7, 2012

Lexicon Pharmaceuticals receives funds to support phase II testing in type 1 diabetes

May 4, 2012

Novel Shp2 inhibitors developed in Germany

May 4, 2012

Transbuccal insulin film produces encouraging first-in-human results

May 4, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...